Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428190801950058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing a noncanonical zinc-binding group as a selective histone deacetylase inhibitor and possible novel anticancer agent.
Bioorg Chem
August 2025
School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:
HDAC inhibitors, which have been proven to be effective for some cancers, have potential as treatments for Non-small cell lung cancer (NSCLC). Building on the core structure of the highly selective HDAC6 inhibitor J22352, we modified various zinc-binding groups of this inhibitor. The resulting compounds 1-8 were designed and synthesized to explore potential derivatives and assess their effects on NSCLC bioactivity.
View Article and Find Full Text PDFSIRT1 as a potential target for age-related eye diseases: mechanisms and therapeutic strategies.
Hum Cell
September 2025
Eye Hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Age-related eye diseases (AREDs) are the leading cause of visual impairment in the elderly, affecting the structure of the anterior and posterior segments of the eye, significantly reducing the quality of life of patients, and even leading to irreversible blindness. Typical AREDs include age-related cataract (ARC), dry eye disease (DED), age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), the global prevalence of which continues to rise, becoming a serious public health concern. SIRT1 is an NAD + dependent deacetylase, which plays an important physiological regulatory role in ocular tissues, mainly affecting gene expression and various cellular processes by regulating the acetylation status of substrate proteins.
View Article and Find Full Text PDFHDAC3 represses Nrf2-GDF11 signaling to drive chondrocyte adipogenesis in temporomandibular joint osteoarthritis.
J Adv Res
September 2025
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi International Joint Research Center for Oral Diseases, Department of Oral Anatomy and Physiology and TMD, School of Stomatology, The Fourth Military Medical Univ
Introduction: Aberrant biomechanical force-induced chondrocyte adipogenesis is involved in the development of temporomandibular joint osteoarthritis (TMJ OA). Growth differentiation factor 11 (GDF11) has been implicated in this process. However, whether mechanosensitive histone deacetylase 3 (HDAC3) regulates GDF11 signaling in the context of TMJ OA remains to be elucidated.
View Article and Find Full Text PDFSelective inhibition of histone deacetylase 3 (HDAC3) prevents vincristine-induced peripheral neuropathy via macrophage polarization.
Neuropharmacology
September 2025
Metabolic Disorders and Neuroscience Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Sciences Pilani, Hyderabad Campus, Hyderabad, India. Electronic address:
Neuroinflammation is vital in vincristine-induced peripheral neuropathy (VIPN). Locally infiltrated macrophages polarize to pro-inflammatory M1-type, release inflammatory cytokines, and contribute to neuropathic pain. Histone deacetylase 3 (HDAC3) regulates macrophage polarization.
View Article and Find Full Text PDFUnlocking the Therapeutic Potential of HDAC Inhibitors in Colorectal Cancer: Mechanisms, Efficacy, and Future Perspectives.
Crit Rev Oncol Hematol
September 2025
Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing100044, China. Electronic address:
Colorectal cancer (CRC) is a predominant malignancy of the digestive tract globally, with primary treatment strategies including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Recently, histone deacetylases (HDACs) and their inhibitors (HDACi) have emerged as promising therapeutic targets in CRC. As critical epigenetic regulators, HDACs influence gene expression and cellular processes, thereby affecting tumor initiation, progression, and immune evasion.
View Article and Find Full Text PDF